Stockreport

Potential Sequential Revenue Run-Rate Growth of 30% over Q1, based on Preliminary April Results

Precipio, Inc.  (PRPO) 
US:NASDAQ Investor Relations: precipiodx.com/investors.html
PDF NEW HAVEN, Conn., May 22, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced accelerating sales of its Patholo [Read more]